In nearly all patients with nasopharyngeal carcinoma (NPC) who are treated with conventional radiotherapy, salivary gland damage with subsequent xerostomia has been unavoidable. 1, 2 To reduce or prevent xerostomia in patients with NPC for whom radiotherapy is mandatory, investigators have used various approaches, including parotidgland-sparing three-dimensional conformal radiotherapy (3DCRT) 3, 4 and intensity-modulated radiotherapy (IMRT), to decrease the dose of radiation delivered to the parotids and increase the dose delivered to the gross disease in the nasopharynx. 5e10 One concern with parotid-gland-sparing radiotherapy is that reducing exposure of the salivary tissue to radiation could result in inadequate radiation exposure to microscopic disease in the region of a spared parotid gland. In 2008, Donald et al first reported on two patients with NPC and one with squamous cell carcinoma of the tonsil who had periparotid failure after definitive parotid-gland-sparing IMRT. 10 These three cases were the only published cases of periparotid treatment failure in patients with head and neck cancer who underwent definitive parotid-glandsparing radiotherapy.
In our institute, three patients who were treated with parotid-gland-sparing radiotherapy later developed periparotid recurrence of NPC. We report our experience with these patients and discuss the clinical implications of periparotid recurrence of NPC.
Patients and methods

Patients
We performed a retrospective chart review of 387 patients with NPC who underwent radiotherapy at the Tri-Service General Hospital, Taipei, Taiwan from 1998 to 2008. Among them, 296 patients underwent parotid-gland-sparing radiotherapy, and only 288 patients who completed the full radiotherapy course were included. Eighty-three patients underwent parotid-gland-sparing 3DCRT and 205 underwent parotid-gland-sparing IMRT. The parotid glands were spared as much as possible with the prerequisite that dose to the target was not compromised. The parotid glands were spared bilaterally in all cases. None of these patients had undergone previous radiotherapy or surgery of the head and neck.
Radiotherapy technique
The 3DCRT technique has been described previously [4] . The clinical target volume (CTV) included the gross target volume (GTV) and the following: the medial pterygoid muscles, the parapharyngeal spaces, the carotid space, the sphenoid sinus, the posterior third to quarter of the nasal cavity, and the anterior quarter to third of the clivus and vertebral body. The lower margin was set at C2 in the absence of oropharyngeal extension. We added 2 mm to all the GTVs to become CTVs, and added 4 mm to all CTVs to become planning target volumes (PTVs). In patients with cavernous sinus or intracranial invasion, the cavernous sinus and the entire sellar and suprasellar regions were included. We added a 4-mm margin to the CTV to allow for setup errors, except at the brainstem and the spinal cord, where the margin was usually 2e4 mm for safety reasons. Thus, the PTV equaled the CTV plus a 4-mm margin. The lower neck and bilateral supraclavicular fossae were irradiated in all patients with 5000 cGy. A single PTV was used throughout the treatment course without reduction.
For IMRT, the simultaneous integrated boost technique was used. CTV1 encompassed the gross tumor with a 0.4-cm margin, CTV2 covered the high-risk areas such as level IIeIII of the neck, and CTV3 included bilateral level IV and supraand infra-clavicular areas. A dose of 6800e7400 cGy was given for PTV1, which encompassed the gross tumor with a margin of 0.4 cm, 6000 cGy to PTV2, and 5000e5400 cGy to PTV3.
Results
Three patients (1.04%) had disease recurrence in a spared parotid gland. Two of them (patients 1 and 2) had undergone parotid-gland-sparing 3DCRT and the third had undergone parotid-gland-sparing IMRT. Two patients (1 and 3) had unilateral nodal disease ipsilateral to the primary tumor. Patient 2 had bilateral lymphadenopathy. Summaries of the patient characteristics before and after periparotid recurrence are provided in Tables 1 and 2 .
Case 1
Pre-therapy computed tomography showed no parotid lesion ( Fig. 1A ). Twenty-one months after having no evidence of disease, the patient noted a swelling over her left preauricular region. Computed tomography demonstrated an enhancing enlarged node in the left periparotid and intraparotid region, suggesting tumor recurrence ( Fig. 1B) . Fine needle aspiration confirmed the presence of a metastatic undifferentiated carcinoma.
Left parotidectomy and neck dissection were performed, and pathological examination showed metastatic undifferentiated carcinoma in the intraparotid and periparotid lymph nodes, with extranodal extension. The margin status showed no malignancy, no extracapsular extension, and no lymphovascular or perineural invasion. The patient underwent adjuvant chemotherapy, and she declined adjuvant radiotherapy. The patient died with bony and intracranial metastases 26 months after recurrence.
Case 2
Pre-therapy magnetic resonance imaging (MRI) showed no parotid lesion ( Fig. 2A ). Six months after having no evidence of disease, the patient noted a swelling in his right pre-auricular region. A superficial nonspecific 7-mm parotid nodule had been noted within the superficial aspect of the right parotid on pretreatment MRI (Fig. 2B) .
Right parotidectomy and neck dissection were performed, and pathological examination showed an intraparotid lymph node of metastatic undifferentiated carcinoma. The margin status showed no malignancy, no extracapsular extension, and no lymphovascular or perineural invasion. The patient declined chemotherapy and underwent IMRT (50 Gy) of the recurrence site. At last follow-up, the patient was well with no evidence of disease 63 months after recurrence.
Case 3
Pre-therapy MRI showed no parotid lesion ( Fig. 3A and 3B) . The patient noted a swelling over his left pre-auricular region 52 months after initial treatment. There was an enlarged mass in the left parotid gland, measuring about 3.3 cm in the long axis, with perifocal edematous changes of the gland (Fig. 3C ). Whole-body bone scan and abdominal sonography revealed no metastasis at other sites. Fine needle aspiration confirmed the presence of a metastatic undifferentiated carcinoma.
Left parotidectomy was performed, and pathological examination showed an intraparotid lymph node of metastatic undifferentiated differentiated carcinoma. The margin status showed no malignancy, no extracapsular extension, and no lymphovascular or perineural invasion. The patient received 45 Gy of IMRT to the recurrence with concurrent chemotherapy and adjuvant chemotherapy. At last followup, 6 months after recurrence, the patient was well with no evidence of disease.
Discussion
The recurrence of head and neck cancer in spared parotid gland was first reported by Chao et al 11 in a patient with hypopharyngeal cancer who had undergone IMRT postoperatively, following partial pharyngectomy and neck dissection. It is possible that, in postoperative patients, altered lymphatic anatomy could contribute to different patterns of locoregional recurrence, and that parotid gland sparing may play only a small role. In 2008, Donald et al reported that two patients with NPC and one with squamous cell carcinoma of the tonsil developed periparotid failure after definitive parotid-gland-sparing IMRT. These three cases were the only published cases of periparotid failure in patients who underwent definitive parotid-gland-sparing IMRT. The authors suggested that the presence of multilevel nodal disease and periparotid nodules on pretreatment imaging should raise suspicion of subclinical disease inside the seemingly harmless nodules, although they do not meet radiographic or clinical criteria for possible gross disease [10] . In our three patients, the cause of recurrence remains elusive. Many factors may contribute to the development of recurrence, including later stage of disease, pre-existing metastasis at the periparotid area, and overprotection of the parotid gland during radiotherapy. Metastasis of NPC may also occur at the parotid nodes. The parotid gland may also be involved by extracapsular spread from enlarged cervical nodes or by direct infiltration by the primary lesion in the nasopharynx. 12 It would seem not powerful enough to draw any conclusions about the exact causes of the recurrence. Among the 288 patients treated with parotid-gland-sparing radiotherapy, periparotid recurrence occurred in only three patients (1.04%). Although there may be more periparotid recurrences during extended follow-up, a significant increase in incidence seems unlikely. In our experience, patients treated with parotid-gland-sparing 3DCRT or IMRT have better overall survival and less xerostomia as compared to patients treated with conventional radiotherapy. 4 The 3-year local control rate and progression-free survival rate of our NPC patients treated with 3DCRT were 86e96% and 80.3%, respectively. 4 Therefore, parotid-gland-sparing 3DCRT or IMRT appear to be worth adopting. The best treatment for periparotid failure after parotidgland-sparing radiotherapy for NPC has not been determined. We chose parotidectomy followed by adjuvant radiotherapy or chemotherapy, or both, as our salvage procedure. Patient 1 in our series died 26 months after recurrence due to bony and intracranial metastasis; the others remained well with no evidence of disease at 63 and 6 months after recurrence, suggesting that aggressive therapy can help to optimize the prognosis for periparotid recurrence. However, regular physical examinations and imaging studies of the parotid gland are required for patients who are treated with parotid-gland-sparing radiotherapy for NPC.
In conclusion, our study shows that periparotid recurrence is an uncommon type of locoregional failure after parotid-gland-sparing radiotherapy for patients with NPC. Although the etiology of periparotid recurrence is unclear, early diagnosis and aggressive treatment of periparotid recurrence may help to optimize outcomes. 
